DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in 12 major mature pharmaceutical markets (Austria, Belgium, Czech Republic, Denmark, Finland, Greece, Netherlands, Norway, Poland , Portugal, Sweden, and Switzerland). We report the prevalence of the disease for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s HD forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HD over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the followingHD subpopulations:
- Diagnosed prevalence of premanifest HD.
- Diagnosed prevalence of manifest HD.
- Diagnosed incident cases of manifest HD.
- Diagnosed population at risk.
- Diagnosed prevalence of manifest HD by stage.
Note: Coverage may vary by country.
- Huntington's Disease - Epidemiology - Europe
Author(s): Nishant Kumar, MPH
Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.
His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.